Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.33 USD
+0.15 (1.34%)
Updated May 14, 2024 04:00 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Roivant Sciences Ltd. [ROIV]
Reports for Purchase
Showing records 21 - 26 ( 26 total )
Company: Roivant Sciences Ltd.
Industry: Unclassified
Roivant Enters Patent Infringement Litigation Against Moderna Regarding LNPs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
On Track for Tapi Launch in Calendar 2Q22 and Details of Hemavant Revealed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Rx for Portfolios, Part 3: Commercial Launches Worth Keeping an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Santa Comes Early With a Gift to Roivant as Appeals Court Rules in Favor of Arbutus and Roivants SNALP Patent; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Lots to Look Forward to for Tapi, 1401, 1801, and the Pipe in Catalyst-Rich 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Roivant Sciences Ltd.
Industry: Unclassified
Doc Survey Suggest Strong Uptake for Tapinarof, While Other Vants Offer Upside; Initiate With Buy and $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D